Requirements for operational cure in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma is typically incurable, but recent therapeutic advances offer new hope.
• Depth of response to treatment is linked to patient outcomes.

Purpose of the Study:

• To discuss the impact of minimal residual disease (MRD) negativity on progression-free survival (PFS) and long-term disease control in multiple myeloma.
• To explore MRD as a surrogate for potential cure.

Main Methods:

• Review of current therapeutic strategies and their impact on MRD status.
• Analysis of factors influencing MRD negativity and its prognostic value, including treatment type, timing, and patient demographics.
• Examination of MRD assessment sensitivity and sustainability.

Main Results:

• Minimal residual disease (MRD) negativity is a strong prognostic factor associated with improved PFS.
• Younger patients receiving intensive therapy (including autologous transplantation) show the highest probability of operational cure.
• Older patients can also achieve operational cure with novel agents like anti-CD38 antibodies.

Conclusions:

• MRD negativity is a key indicator for achieving long-term disease control and potential cure in multiple myeloma.
• Incorporating MRD as a surrogate endpoint in clinical trials can personalize treatment and accelerate the path to cure.
• Future protocols involving novel immunotherapies hold promise for older patients.